The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.
Mehul BhattacharyyaLarry E MillerAnna L MillerRuemon BhattacharyyaPublished in: Expert opinion on biological therapy (2024)